Lipids, liver and pancreas at the crossroads of metabolic syndrome and obesity epidemics
The prevalence of metabolic syndrome (MS), non-alcoholic fatty liver disease (NAFLD) and non-alcoholic fatty pancreatic disease (NAFPD) is 1/4–1/3 of the planet population. It has been proven that the main links in their pathogenesis are disorders of lipid and carbohydrate metabolism. A high comorbi...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Siberian Branch of Russian Academy of Sciences, Research Institute of Internal and Preventive Medicine, branch of the Institute of Cytology and Genetics
2020-12-01
|
| Series: | Атеросклероз |
| Subjects: | |
| Online Access: | https://ateroskleroz.elpub.ru/jour/article/view/402/382 |
| _version_ | 1797966172785737728 |
|---|---|
| author | O. V. Efimova I. N. Grigor'eva N. L. Tov T. S. Suvorova D. L. Nepomnyashchikh T. I. Romanova |
| author_facet | O. V. Efimova I. N. Grigor'eva N. L. Tov T. S. Suvorova D. L. Nepomnyashchikh T. I. Romanova |
| author_sort | O. V. Efimova |
| collection | DOAJ |
| description | The prevalence of metabolic syndrome (MS), non-alcoholic fatty liver disease (NAFLD) and non-alcoholic fatty pancreatic disease (NAFPD) is 1/4–1/3 of the planet population. It has been proven that the main links in their pathogenesis are disorders of lipid and carbohydrate metabolism. A high comorbidity of NAFLD and NAFPD was shown: in 67,9 % of patients with NAFPD, fatty liver was revealed, and in 96,8 % of patients with NAFLD, pancreatic steatosis was diagnosed. The prevalence of MC among NAFPD patients is 59,2–76,9 %. A meta-analysis revealed that NAFPD is associated with an increased risk of MS (relative risk (RR) = 2,25; 95 % CI 2,00–2,53; p < 0,0001), arterial hypertension (RR = 1,43; 95 % CI 1,08–1,90; p = 0,013), NAFLD (RR = 2,49; 95 % CI 2,06–3,02; p < 0,0001), diabetes mellitus 2 type (RR = 1,99; 95 % CI 1,18–3,35; p = 0,01), and obesity (RR = 1,91; 95 % CI 1,67–2,19; p < 0,0001). Concomitant MS negatively affects the clinical course of acute and chronic pancreatitis, for example, moderately severe acute pancreatitis is observed 3 times more often with MS than without MS, partly due to that I, IV and V types of hyperlipidemia are associated with acute pancreatitis. Dyslipidemia in NAFLD occurs in 60–70 % of cases and is characterized by hypertriglyceridemia, elevated level of free fatty acids and low density lipoprotein cholesterol, decreased content of high density lipoprotein cholesterol. Therefore, strategies aimed at the primary prevention of dyslipidemia can help reduce morbidity and mortality in liver and pancreatic pathology associated with MS. |
| first_indexed | 2024-04-11T02:11:33Z |
| format | Article |
| id | doaj.art-4829883429144348a0562e9e5ea3ba3e |
| institution | Directory Open Access Journal |
| issn | 2078-256X |
| language | Russian |
| last_indexed | 2024-04-11T02:11:33Z |
| publishDate | 2020-12-01 |
| publisher | Siberian Branch of Russian Academy of Sciences, Research Institute of Internal and Preventive Medicine, branch of the Institute of Cytology and Genetics |
| record_format | Article |
| series | Атеросклероз |
| spelling | doaj.art-4829883429144348a0562e9e5ea3ba3e2023-01-03T02:01:47ZrusSiberian Branch of Russian Academy of Sciences, Research Institute of Internal and Preventive Medicine, branch of the Institute of Cytology and GeneticsАтеросклероз2078-256X2020-12-011647784https://doi.org/10.15372/ATER20200410Lipids, liver and pancreas at the crossroads of metabolic syndrome and obesity epidemicsO. V. Efimova0https://orcid.org/0000-0003-1874-8458I. N. Grigor'eva1https://orcid.org/0000-0003-0069-7744N. L. Tov2T. S. Suvorova3https://orcid.org/0000-0001-5809-2241D. L. Nepomnyashchikh4T. I. Romanova5https://orcid.org/0000-0001-8514-2304State Budgetary Healthcare Institution «City Infectious Diseases Clinical Hospital № 1» Russian FederationResearch Institute of Internal and Preventive Medicine – Branch of Federal Research Center Institute of Cytology and Genetics of SB RAS Russian FederationNovosibirsk State Medical University of Minzdrav of Russia Russian FederationNovosibirsk State Medical University of Minzdrav of Russia Russian FederationNovosibirsk State Medical University of Minzdrav of Russia Russian FederationResearch Institute of Internal and Preventive Medicine – Branch of Federal Research Center Institute of Cytology and Genetics of SB RAS Russian FederationThe prevalence of metabolic syndrome (MS), non-alcoholic fatty liver disease (NAFLD) and non-alcoholic fatty pancreatic disease (NAFPD) is 1/4–1/3 of the planet population. It has been proven that the main links in their pathogenesis are disorders of lipid and carbohydrate metabolism. A high comorbidity of NAFLD and NAFPD was shown: in 67,9 % of patients with NAFPD, fatty liver was revealed, and in 96,8 % of patients with NAFLD, pancreatic steatosis was diagnosed. The prevalence of MC among NAFPD patients is 59,2–76,9 %. A meta-analysis revealed that NAFPD is associated with an increased risk of MS (relative risk (RR) = 2,25; 95 % CI 2,00–2,53; p < 0,0001), arterial hypertension (RR = 1,43; 95 % CI 1,08–1,90; p = 0,013), NAFLD (RR = 2,49; 95 % CI 2,06–3,02; p < 0,0001), diabetes mellitus 2 type (RR = 1,99; 95 % CI 1,18–3,35; p = 0,01), and obesity (RR = 1,91; 95 % CI 1,67–2,19; p < 0,0001). Concomitant MS negatively affects the clinical course of acute and chronic pancreatitis, for example, moderately severe acute pancreatitis is observed 3 times more often with MS than without MS, partly due to that I, IV and V types of hyperlipidemia are associated with acute pancreatitis. Dyslipidemia in NAFLD occurs in 60–70 % of cases and is characterized by hypertriglyceridemia, elevated level of free fatty acids and low density lipoprotein cholesterol, decreased content of high density lipoprotein cholesterol. Therefore, strategies aimed at the primary prevention of dyslipidemia can help reduce morbidity and mortality in liver and pancreatic pathology associated with MS.https://ateroskleroz.elpub.ru/jour/article/view/402/382metabolic syndromenon-alcoholic fatty pancreatic diseasenon-alcoholic fatty liver diseaseacute pancreatitischronic pancreatitisblood lipids |
| spellingShingle | O. V. Efimova I. N. Grigor'eva N. L. Tov T. S. Suvorova D. L. Nepomnyashchikh T. I. Romanova Lipids, liver and pancreas at the crossroads of metabolic syndrome and obesity epidemics Атеросклероз metabolic syndrome non-alcoholic fatty pancreatic disease non-alcoholic fatty liver disease acute pancreatitis chronic pancreatitis blood lipids |
| title | Lipids, liver and pancreas at the crossroads of metabolic syndrome and obesity epidemics |
| title_full | Lipids, liver and pancreas at the crossroads of metabolic syndrome and obesity epidemics |
| title_fullStr | Lipids, liver and pancreas at the crossroads of metabolic syndrome and obesity epidemics |
| title_full_unstemmed | Lipids, liver and pancreas at the crossroads of metabolic syndrome and obesity epidemics |
| title_short | Lipids, liver and pancreas at the crossroads of metabolic syndrome and obesity epidemics |
| title_sort | lipids liver and pancreas at the crossroads of metabolic syndrome and obesity epidemics |
| topic | metabolic syndrome non-alcoholic fatty pancreatic disease non-alcoholic fatty liver disease acute pancreatitis chronic pancreatitis blood lipids |
| url | https://ateroskleroz.elpub.ru/jour/article/view/402/382 |
| work_keys_str_mv | AT ovefimova lipidsliverandpancreasatthecrossroadsofmetabolicsyndromeandobesityepidemics AT ingrigoreva lipidsliverandpancreasatthecrossroadsofmetabolicsyndromeandobesityepidemics AT nltov lipidsliverandpancreasatthecrossroadsofmetabolicsyndromeandobesityepidemics AT tssuvorova lipidsliverandpancreasatthecrossroadsofmetabolicsyndromeandobesityepidemics AT dlnepomnyashchikh lipidsliverandpancreasatthecrossroadsofmetabolicsyndromeandobesityepidemics AT tiromanova lipidsliverandpancreasatthecrossroadsofmetabolicsyndromeandobesityepidemics |